Table 4

Risk of Vascular Events by HDL-C in Categories of Increasingly Potent Lipid-Lowering Therapy

Category of Lipid-Lowering Therapyn (Events)LDL-C Level (mmol/l)Risk for Vascular Events Per 0.1 mmol/l Increase
Model 1Model 2Model 3
1 (1% to <30%)763 (114)2.9 ± 0.80.92 (0.86–0.98)0.93 (0.87–1.00)0.95 (0.88–1.02)
2 (30% to <40%)1,144 (148)2.7 ± 0.80.93 (0.88–0.99)0.93 (0.88–0.99)0.94 (0.88–1.00)
3 (40% to <45%)1,310 (92)2.4 ± 0.80.98 (0.92–1.04)0.99 (0.93–1.05)1.01 (0.95–1.07)
4 (≥45%)735 (65)2.3 ± 0.91.02 (0.95–1.10)1.04 (0.97–1.13)1.06 (0.99–1.15)
p value for interaction lipid-lowering therapy × HDL-C0.030.030.03

Categories of lipid-lowering therapy were defined according to theoretical LDL-C reduction: 1% to <30%, 30% to <40%, 40% to <45%, and <45%. Model 1: adjusted for age and sex. Model 2: Model 1 + type 2 diabetes mellitus, body mass index, and plasma triglyceride levels. Model 3: Model 2 + smoking and alcohol.

Abbreviations as in Table 1.